# CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Article · Yongxian Hu, Yali Zhou, Mingming Zhang, Wengang Ge, Yi Li, Li Yang, Guoqing Wei, Lu Han, Hao Wang, Shuhui Yu, Yi Chen, Yanbin Wang, Xiaohong He, Xingwang Zhang, Ming Jing Gao, Jingjing Yang, Xiuju Li, Jiangtao Ren, He Huang

- Archive id: doi:10.1158/1078-0432.ccr-20-3863
- Published: 2021-02-24
- Venue: Clinical Cancer Research
- DOI: https://doi.org/10.1158/1078-0432.ccr-20-3863
- PMID: 33627493
- Citations: 281
- Source URL: https://doi.org/10.1158/1078-0432.ccr-20-3863
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.